Tumors suffer metabolic stress, such as oxygen and nutrient deficiency; as a result, altered metabolism is a common feature of tumors. Cancer cells enhance the production of energy and the synthesis of macromolecules to grow at pathologically increased rates. It is crucial to identify genes that modulate cellular fitness under these stressful scenarios. Read More
With $70 million in hand, Excellergy Inc. is ready to advance its lead candidate for allergic diseases into clinical trials. The series A round was led by Samsara Biocapital with co-investments from Red Tree Venture Capital and Decheng Capital. Read More
A recent study published in PLOS Genetics has identified several novel genetic variants associated with the risk of orofacial clefts, a common and complex congenital disability. Orofacial clefts are caused by a combination of genetic and environmental factors and can occur in isolation or simultaneously with other birth defects. Read More
Amphista Therapeutics Ltd. has nominated AMX-883, a selective and orally bioavailable degrader of BRD9, as its first clinical development candidate. AMX-883 is being advanced for the treatment of acute myeloid leukemia (AML), with an IND application planned for early next year. Read More
BioWorld Staff Writer Tamra Sami says it’s impossible to talk about changes to the biotech and med-tech landscape in Asia without discussing China, which is eclipsing the region. In the last two decades, China has shifted from imitator to innovator. Read More
Nuphase Therapeutics (Shanghai) Co. Ltd. has disclosed compounds acting as interleukin-17A/A homodimer and IL-17A/F heterodimer inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory diseases. Read More
Researchers at Indian Institute of Technology (BHU) Varanasi and collaborators have designed inhibitors of cholinesterase based on benzothiazole-phenylpiperizine as a potential treatment for Alzheimer’s disease. Read More
Pyrotech (Beijing) Biotechnology Co. Ltd. has identified gasdermin-E (GSDME) inhibitors reported to be useful for the treatment of genetic diseases, cancer, viral infection, age-related macular degeneration, autoimmune diseases, neurological disorders, renal disorders and cancer therapy-associated disorders. Read More
NOD2 deficiency is involved in the pathogenesis of Crohn’s disease (CD) due to failure of gut innate immunity and loss of intestinal tissue homeostasis. Orchard Therapeutics Ltd. has presented preclinical data on OTL-104, human hematopoietic stem cell (HSC) gene therapy for the treatment of NOD2-deficient CD.
Scientists at Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. have divulged histone acetyltransferase KAT6A (MOZ; MYST-3) and histone acetyltransferase KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of breast cancer. Read More
Researchers at Dongguk University and Korean Research Institute of Bioscience and Biotechnology have described oxazole derivatives acting as malate dehydrogenase, cytoplasmic (MDH1) and/or malate dehydrogenase, mitochondrial (MDH2) inhibitors reported to be useful for the treatment of cancer. Read More
As part of global efforts to develop next-generation antibiotics to overcome the growing problem of bacterial resistance to existing drugs, researchers at the Lanzhou Institute of Husbandry and Pharmaceutical Sciences prepared various derivatives of the dimethylcysteamine form of pleuromutilin, a naturally occurring diterpenoid. Read More
